Trials / Completed
CompletedNCT00422019
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 102 at 10 mg/kg | AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks |
| DRUG | AMG 102 at 20 mg/kg | AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2007-01-15
- Last updated
- 2015-04-10
Source: ClinicalTrials.gov record NCT00422019. Inclusion in this directory is not an endorsement.